



OPEN ACCESS

EDITED AND REVIEWED BY
Michael G. Brown,
University of Virginia, United States

*CORRESPONDENCE
Nobuyo Yawata
✉ yawata.nobuyo.718@m.kyushu-
u.ac.jp

SPECIALTY SECTION
This article was submitted to
NK and Innate Lymphoid Cell Biology,
a section of the journal
Frontiers in Immunology

RECEIVED 15 December 2022

ACCEPTED 16 December 2022

PUBLISHED 05 January 2023

CITATION

Shirane M, Yawata N, Motoooka D, Shibata K, Khor S-S, Omae Y, Kaburaki T, Yanai R, Mashimo H, Yamana S, Ito T, Hayashida A, Mori Y, Numata A, Murakami Y, Fujiwara K, Ohguro N, Hosogai M, Akiyama M, Hasegawa E, Paley M, Takeda A, Maenaka K, Akashi K, Yokoyama WM, Tokunaga K, Yawata M and Sonoda K-H (2023) Corrigendum: Intraocular human cytomegaloviruses of ocular diseases are distinct from those of viremia and are capable of escaping from innate and adaptive immunity by exploiting HLA-E-mediated peripheral and central tolerance.

Front. Immunol. 13:1124440.
doi: 10.3389/fimmu.2022.1124440

COPYRIGHT

© 2023 Shirane, Yawata, Motoooka, Shibata, Khor, Omae, Kaburaki, Yanai, Mashimo, Yamana, Ito, Hayashida, Mori, Numata, Murakami, Fujiwara, Ohguro, Hosogai, Akiyama, Hasegawa, Paley, Takeda, Maenaka, Akashi, Yokoyama, Tokunaga, Yawata and Sonoda. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Intraocular human cytomegaloviruses of ocular diseases are distinct from those of viremia and are capable of escaping from innate and adaptive immunity by exploiting HLA-E-mediated peripheral and central tolerance

Mariko Shirane¹, Nobuyo Yawata^{2,3,4*}, Daisuke Motoooka^{5,6}, Kensuke Shibata^{2,7,8}, Seik-Soon Khor⁹, Yosuke Omae⁹, Toshikatsu Kaburaki^{10,11}, Ryoji Yanai¹², Hisashi Mashimo¹³, Satoshi Yamana¹, Takako Ito¹, Akira Hayashida¹, Yasuo Mori¹⁴, Akihiko Numata¹⁴, Yusuke Murakami¹, Kohta Fujiwara¹, Nobuyuki Ohguro¹³, Mayumi Hosogai¹⁵, Masato Akiyama², Eiichi Hasegawa¹, Michael Paley¹⁶, Atsunobu Takeda¹, Katsumi Maenaka^{17,18,19}, Koichi Akashi¹⁴, Wayne M. Yokoyama^{16,20}, Katsushi Tokunaga⁹, Makoto Yawata^{21,22,23,24,25,26} and Koh-Hei Sonoda¹

¹Department of Ophthalmology, Kyushu University, Fukuoka, Japan, ²Department of Ocular Pathology and Imaging Science, Kyushu University, Fukuoka, Japan, ³Ocular Inflammation and Immunology, Singapore Eye Research Institute, Singapore, Singapore, ⁴Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore,

⁵Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan, ⁶Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Osaka, Japan,

⁷Department of Microbiology and Immunology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan, ⁸Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan, ⁹Genome Medical Science Project, National Center for Global Health and Medicine, Tokyo, Japan, ¹⁰Department of Ophthalmology, The University of Tokyo Hospital, Tokyo, Japan, ¹¹Department of Ophthalmology, Jichi Medical University Saitama Medical Center, Saitama, Japan, ¹²Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, ¹³Department of Ophthalmology, Japan Community Health Care Organization Hospital, Osaka, Japan, ¹⁴Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan,

¹⁵Department of Ophthalmology, Gunma University Graduate School of Medicine, Gunma, Japan, ¹⁶Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States,

¹⁷Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan, ¹⁸Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan, ¹⁹Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan, ²⁰Bursky Center for Human Immunology and Immunotherapy Programs, Washington University, St. Louis, MO, United States, ²¹Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research, ASTAR, Singapore, Singapore, ²²Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, ²³Department of Pediatrics, National University

Health System, Singapore, Singapore, ²⁴Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore, ²⁵National University Singapore Medicine Immunology Translational Research Programme, National University of Singapore, Singapore, Singapore, ²⁶International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan

KEYWORDS

human cytomegalovirus, HLA-E, UL40, natural killer cells, HLA class I, NKG2A, CMV viremia, CMV retinitis

A Corrigendum on

Intraocular human cytomegaloviruses of ocular diseases are distinct from those of viremia and are capable of escaping from innate and adaptive immunity by exploiting HLA-E-mediated peripheral and central tolerance

by Shirane M, Yawata N, Motoooka D, Shibata K, Khor S-S, Omae Y, Kaburaki T, Yanai R, Mashimo H, Yamana S, Ito T, Hayashida A, Mori Y, Numata A, Murakami Y, Fujiwara K, Ohguro N, Hosogai M, Akiyama M, Hasegawa E, Paley M, Takeda A, Maenaka K, Akashi K, Yokoyama WM, Tokunaga K, Yawata M and Sonoda K-H (2022) *Front. Immunol.* 13:1008220. doi: 10.3389/fimmu.2022.1008220

In the published article, there were errors. In the original article, there was an error in the description of the Reverse primer sequence in **Materials and methods**.

A correction has been made to **Materials and methods**, “*Deep amplicon sequencing of CMV-UL40 genomic DNA*”.

This sentence previously stated:

“The following forward and reverse primers were used: Forward, 5'-TCGTCGGCAGCGTCAGATGTGTATAAG AGACAGCAACAGTCGGCAGAACATGAAC-3' and Reverse, 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACA GCTGGAACACGACGCATA-3'.”

The corrected sentence appears below:

“The following forward and reverse primers were used: Forward, 5'-TCGTCGGCAGCGTCAGATGTGTATAA GAGACAGCAACAGTCGGCAGAACATGAAC-3' and Reverse, 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGAC AGCTGGAACACGAGCGGACATA-3'.”

In the original article, there was another error in the description of the concentration of the anti-HLA-E antibody in **Materials and methods**.

A correction has been made to **Materials and methods**, “*Immunohistochemistry analysis*”.

This sentence previously stated:

“After antigen retrieval with boiling citrate buffer (pH 6.0), the sections were incubated with 5% skim milk for 1 h at room

temperature to prevent nonspecific binding and stained with 10 µL/mL anti-HLA-E antibody [MEM-E/02] (Abcam; Cambridge, UK) or IgG from mouse serum (Sigma-Aldrich) overnight at 4°C.”

The corrected sentence appears below:

“After antigen retrieval with boiling citrate buffer (pH 6.0), the sections were incubated with 5% skim milk for 1 h at room temperature to prevent nonspecific binding and stained with 10 µg/mL anti-HLA-E antibody [MEM-E/02] (Abcam; Cambridge, UK) or IgG from mouse serum (Sigma-Aldrich) overnight at 4°C.”

The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.